CHOROIDEREMIA RESEARCH FOUNDATION STRENGTHENS LEADERSHIP
Four New Members Join the Board of Directors Springfield, MA., July 16, 2020 The Choroideremia Research Foundation (CRF) is pleased
Kim Edwards Receives 1st Annual CRF Randy Wheelock Research Award
Choroideremia Research Foundation Awards $50,000 Grant in New Program Springfield, MA., May 26, 2020 The Choroideremia Research Foundation (CRF) is
Choroideremia Research Foundation Announces Funding Grant for CHM Research
Dr. David Williams at UCLA to begin mitochondrial defects study to help find a cure for Choroideremia Springfield, MA., March
The Choroideremia Research Foundation Announces Funding Grants for CHM Research
The CRF awards three research grants totaling $219,000 to continue leading efforts to find a cure for Choroideremia Springfield, MA.,
The Choroideremia Research Foundation Announces First Annual Randy Wheelock Research Award
Researchers may submit proposals for projects related to finding a cure for CHM by November 15, 2019 Springfield, MA., October
The Choroideremia Research Foundation Announces New Executive Director and Chief Medical Officer
The Choroideremia Research Foundation announced the appointment of Kathi Wagner to the position of Executive Director and Chris Moen, MD
Choroideremia Research Foundation Holds 2019 International Choroideremia Symposium
On June 6-7, the Choroideremia Research Foundation (CRF) hosted its 2019 International Choroideremia Symposium in Philadelphia, Pennsylvania. With the support
4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products
4D Molecular Therapeutics (4DMT), a leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product
Nightstar Announces First-Ever Phase 3 Choroideremia Gene Therapy Trial
Nightstar Therapeutics has announced the initiation of the company’s STAR Phase 3 registrational trial to study the safety and efficacy of
Nightstar Therapeutics raises $75 Million in IPO to fund Pivotal Phase 3 Gene Therapy Study
Nightstar Therapeutics held it’s Initial Public Offering on Thursday September 28th, raising $75 Million which will be used to advance the